ChemicalBook >> CAS DataBase List >>Emibetuzumab

Emibetuzumab

CAS No.
1365287-97-3
Chemical Name:
Emibetuzumab
Synonyms
LY2875358;Emibetuzumab;Emibetuzumab (anti-MET);Research Grade Emibetuzumab;Research Grade Emibetuzumab(DHC34201)
CBNumber:
CB28080907
Molecular Formula:
Molecular Weight:
0
MDL Number:
MOL File:
Mol file
MSDS File:
SDS
Last updated:2026-04-24 14:59:02

Emibetuzumab Properties

form Liquid
color Colorless to light yellow
FDA UNII MO4K3GDN1I

Emibetuzumab price

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
ChemScene CS-0612940 Emibetuzumab 95.00% 1365287-97-3 1mg $195 2026-06-04 Buy
ChemScene CS-0612940 Emibetuzumab 95.00% 1365287-97-3 5mg $585 2026-06-04 Buy
ChemScene CS-0612940 Emibetuzumab 95.00% 1365287-97-3 10mg $932 2026-06-04 Buy
aablocks AA02A8IR Emibetuzumab 1365287-97-3 1mg $138 2026-06-02 Buy
aablocks AA02A8IR Emibetuzumab 1365287-97-3 5mg $378 2026-06-02 Buy
Product number Packaging Price Buy
CS-0612940 1mg $195 Buy
CS-0612940 5mg $585 Buy
CS-0612940 10mg $932 Buy
AA02A8IR 1mg $138 Buy
AA02A8IR 5mg $378 Buy

Emibetuzumab Chemical Properties,Uses,Production

Description

Emibetuzumab is a bivalent antibody that blocks HGF- and MET-receptor interaction, leading to MET internalization and degradation.

Uses

Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer[1].

Clinical Use

A phase I study determined a tolerable dose for emibetuzumab to be 700–2000 mg as a monotherapy and in combination with erlotinib in NSCLC patients. It is currently being investigated in phase II in combination with erlotinib.

in vivo

Emibetuzumab (LY2875358) (10 mg/kg; i.v.; once a week for 5 weeks) inhibits in vivo growth of glioblastoma U87MG xenograft tumors in mice[1].
Emibetuzumab (10 or 20 mg/kg; i.v.; single) downregulates levels of MET and pMET in the tumors of mice[1].
Emibetuzumab (10 mg/kg; i.v.; once a week for 3, 5 or 6 weeks) exhibits antitumor effects on MET-amplified xenograft mouse tumor models[1].

Animal Model:Athymic nude mice (U87MG tumor xenograft model)[1].
Dosage:10 mg/kg
Administration:Intravenous injection, once a week for 5 weeks.
Result:Demonstrated a significant inhibition of tumor growth.
Animal Model:Athymic nude mice (MKN45 xenograft tumor model)[1].
Dosage:10 or 20 mg/kg
Administration:Intravenous injection, single.
Result:Reduced MET and pMET in the tumors by approximately 50% at both the 10 and 20 mg/kg doses by 72 hours post dose, and the reductions persisted to 14 days.
Animal Model:Athymic nude mice (MET-amplified xenograft mouse tumor models)[1].
Dosage:10 mg/kg
Administration:Intravenous injection, once a week for 3, 5 or 6 weeks.
Result:Resulted in a marked reduction in tumor growth in the MKN45/SNU-5/EBC-1 gastric xenograft tumors.

References

[1] Liu L, et al. LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth. Clin Cancer Res. 2014 Dec 1;20(23):6059-70. DOI:10.1158/1078-0432.CCR-14-0543

Emibetuzumab Preparation Products And Raw materials

Raw materials

Preparation Products

Emibetuzumab Suppliers

Global( 25)Suppliers
Supplier Tel Email Country ProdList Advantage
Shanghai YuanYe Biotechnology Co., Ltd. 15026964105 2881489226@qq.com China 89667 60
ShangHai Biochempartner Co.,Ltd 177-54423994 17754423994 2853530910@QQ.com China 8000 62
BOC Sciences 16314854226; +8616314854226 inquiry@bocsci.com United States 19852 58
Guangzhou Hongyuan Chemical Co.,Ltd 15817493340 981810490@qq.com China 1577 58
Wuhan Chemstan Biotechnology Co., Ltd. 027-65317797 15926423062 422450190@qq.com China 10305 58
Beijing Jin Ming Biotechnology Co., Ltd. 010-60605840 psaitong@jm-bio.com China 27626 58
TargetMol Chemicals Inc. 4008200310 15002144251 marketing@tsbiochem.com China 24951 58
Biolab Reagents 027-65279366 18108604356 products@biolabreagent.com China 9864 58
Wuhan Jingkangen Biomedical Technology Co., Ltd 13720134139 086-15871494362 13720134139 orders@jknbiochem.com China 7283 58
Shanghai Yifei Biotechnology Co. , Ltd. 021-65675885 18964387627 customer_service@efebio.com China 11963 58
Emibetuzumab Research Grade Emibetuzumab(DHC34201) Emibetuzumab (anti-MET) LY2875358 Research Grade Emibetuzumab 1365287-97-3